Angelini Ventures
Corporate venture capital
RollingLast verified 7 Nov 2026
Corporate venture arm of Angelini Industries investing in Series A and Series B rounds of biotech and healthtech companies across Europe and North America.
3 deals in the last 24 months, latest 6 Oct 2026. From its website and its deals in the news.
Key facts
- Stages
- Series A, Series B
- Sectors
- Biotech & pharma, Healthtech
- Typical round size
- €51.9M (median of its recent deals, not a ticket)
- Eligible countries
- Not stated
- Provider based in
- Italy
- Timing
- Rolling applications
- Focus
- BioTech and HealthTech; Series A and Series B; novel biological approaches; digital care platforms and medical devices
- How to apply
- Apply route unknown
Recent deals
| Company | Round | Sectors | Amount | Role | Announced |
|---|---|---|---|---|---|
| RougeTx | Series A | Biotech & pharma, Healthtech | €51.9M | lead | 6 Oct 2026 |
| Adcytherix | Series A | Biotech & pharma | €105M | – | 16 Oct 2025 |
| Vantis Health | Series A | Healthtech, AI & machine learning | €10M | lead | 12 Mar 2025 |
Evidence
Short excerpts from the sources, in their original language, that back the facts above.
- Kind
Part of Angelini Industries
https://www.angeliniventures.com/approach - Sectors
companies operating in BioTech and HealthTech with significant potential to improve human health
https://www.angeliniventures.com/approach - Stages
We invest in Series A and Series B rounds of companies operating in BioTech and HealthTech
https://www.angeliniventures.com/approach
Status history
- 7 Nov 2026: Uncertain → Rolling (profiles: investor activity)
- 7 Nov 2026: Rolling → Uncertain (freshness: investor activity)
- 6 Nov 2026: Rolling (first extraction)
Something wrong or out of date? Report an error.
Work at Angelini Ventures? Claim this profile to confirm what you invest in.